Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the

application.

Listing of Claims:

1. (withdrawn) A method of providing a therapeutic protein to a customer, said method

comprising cloning a nucleic acid encoding said protein into a pCWinl expression vector

as set forth in SEQ ID NO:1, expressing said protein therefrom, and providing said

protein to said customer.

2. (original) A method of providing a therapeutic protein to a customer, said method

comprising cloning a nucleic acid encoding said protein into a pCWin2 expression vector

as set forth in SEO ID NO:2, expressing said protein therefrom, and providing said

protein to said customer.

3. (original) A method of providing a therapeutic protein to a customer, said method

comprising cloning a nucleic acid encoding said protein into a nucleic acid vector

selected from the group consisting of:

a) a pCWin2/MBP expression vector as set forth in SEQ ID NO:3;

b) a pCWin2-MBP-SBD (pMS₃₉) expression vector as set forth in SEQ ID NO:10; and

c) a pCWin2-MBP-MCS-SBD (pMXSp₃₉) expression vector as set forth in SEQ ID

NO:11;

expressing said protein therefrom, and providing said protein to said customer.

4. (original) The method of claim 3, wherein said nucleic acid vector comprises a

protease cleavage site coding sequence at a location selected from the group consisting

of:

a) between the MBP coding sequence and the therapeutic protein coding sequence; and

b) immediately prior to the start of the C-terminus of the MBP coding sequence.

{W:\DOCS\NJPC\1096\0011us1\00015820.DOC} US Ser No: 10/585,440

US Ser No: 10/585,440 Appl. Filed: 05/08/2007

5. (original) The method of claim 2 or 3, wherein said protein is selected from the group

consisting of erythropoietin, human growth hormone, granulocyte colony stimulating

factor, interferons alpha, -beta, and -gamma, Factor IX, follicle stimulating hormone,

interleukin-2, erythropoietin, anti-TNF-alpha, and a lysosomal hydrolase.

6. (original) The method of claim 5, wherein said lysosomal hydrolase is selected from

the group consisting of beta-glucosidase, alpha-galactosidase-A, beta-hexosaminidase,

beta-galactosidase, alpha-galactosidase, alpha-mannosidase, beta-mannosidase, alpha-L-

fucosidase, beta-glucuronidase, alpha-glucosidase, alpha-N-acetylgalactosaminidase, and

acid phosphatase.

7. (withdrawn) A method of providing a protein to a customer, said method comprising

cloning a nucleic acid encoding said protein into a pCWin1 expression vector as set forth

in SEQ ID NO:1, expressing said protein therefrom, and providing said protein to said

customer.

8. (original) A method of providing a protein to a customer, said method comprising

cloning a nucleic acid encoding said protein into a pCWin2 expression vector as set forth

in SEQ ID NO:2, expressing said protein therefrom, and providing said protein to said

customer.

9. (original) A method of providing a protein to a customer, said method comprising

cloning a nucleic acid encoding said protein into a nucleic acid vector selected from the

group consisting of:

a) a pCWin2/MBP expression vector as set forth in SEQ ID NO:3;

b) a pCWin2-MBP-SBD (pMS₃₉) expression vector as set forth in SEQ ID NO:10; and

3

c) a pCWin2-MBP-MCS-SBD (pMXS₃₉) expression vector as set forth in SEQ ID

NO:11;

expressing said protein therefrom, and providing said protein to said customer.

{W:\DOCS\NJPC\1096\0011us1\000015820.DOC} US Ser No: 10/585,440

Appl. Filed: 05/08/2007

10. (original) The method of claim 7, 8 or 9, wherein said protein is selected from the

group consisting of a glycosyltransferase and a sugar nucleotide-generating enzyme.

11. (withdrawn) A method of providing a protein to a customer, said method comprising

providing a pCWin1 vector as set forth in SEQ ID NO:1 to a protein production facility,

wherein a nucleic acid encoding said protein is cloned into said expression vector and

said protein is expressed therefrom in said protein production facility, and providing said

protein to said customer.

12. (original) A method of providing a protein to a customer, said method comprising

providing a pCWin2 vector as set forth in SEQ ID NO:2 to a protein production facility,

wherein a nucleic acid encoding said protein is cloned into said expression vector and

said protein is expressed therefrom in said protein production facility, and providing said

protein to said customer.

13. (original) A method of providing a protein to a customer, said method comprising

providing a nucleic acid vector selected from the group consisting of:

a) a pCWin2/MBP expression vector as set forth in SEQ ID NO:3;

b) a pCWin2-MBP-SBD (pMS₃₉) expression vector as set forth in SEQ ID NO:10; and

c) a pCWin2-MBP-MCS-SBD (pMXS₃₉) expression vector as set forth in SEQ ID

NO:11:

to a protein production facility, wherein a nucleic acid encoding said protein is cloned

into said expression vector and said protein is expressed therefrom in said protein

production facility, and providing said protein to said customer.

14. (currently amended) The method of claim 2, 3, 4, [[7,]] 8 or 9, wherein said method

further comprises prior to providing said protein to said customer, at least one glycosyl

moiety is added to said protein.

15. (original) The method of claim 14, wherein said glycosyl moiety is added to said

protein in vitro.

{W:\DOCS\NJPC\1096\0011us1\00015820.DOC} US Ser No: 10/585,440

US Ser No: 10/585,440 Appl. Filed: 05/08/2007

16. (currently amended) A method of providing a protein to a customer, said method comprising cloning a nucleic acid encoding said protein into-nucleic acid vector selected from the group consisting of:

a) a pCWin1 vector as set forth in SEQ ID NO:1;

b) a) a pCWin2 vector as set forth in SEQ ID NO:2;

e) b) a pCWin2/MBP vector as set forth in SEQ ID NO:3;

d) c) a pCWin2-MBP-SBD (pMS₃₉) vector as set forth in SEQ ID NO:10; and

e) d) a pCWin2-MBP-MCS-SBD (pMXS₃₉) vector as set forth in SEQ ID NO:11;

further wherein said method comprises inserting said vector into a bacterial host cell,

expressing said protein in said host cell, and providing said protein to said customer.

17. (original) The method of claim 16, wherein said method further comprises prior to

providing said protein to said customer, at least one glycosyl moiety is added to said

protein.

18. (original) The method of claim 16, wherein said glycosyl moiety is added to said

protein in vitro.

19. (original) The method of claim 16, wherein said expression vector further comprises

an affinity tag coding sequence.

20. (withdrawn) An isolated pcWIN1 expression vector comprising the sequence set

forth in SEQ ID NO:1.

21. (withdrawn) An isolated pcWIN1 expression vector consisting of the sequence set

forth in SEQ ID NO:1.

22. (original) An isolated pcWIN2 expression vector comprising the sequence set forth

5

in SEQ ID NO:2.

{W:\DOCS\NJPC\1096\0011us1\00015820.DOC} US Ser No: 10/585,440

Appl. Filed: 05/08/2007

23. (original) An isolated pcWIN2 expression vector consisting of the sequence set forth

in SEQ ID NO:2.

24. (original) An isolated pcWIN2/MBP expression vector comprising the sequence set

forth in SEQ ID NO:3.

25. (original) An isolated pcWIN2/MBP expression vector consisting of the sequence

set forth in SEQ ID NO:3.

26. (original) The pcWIN280P expression vector of claim 24, wherein the pCWIN2/MBP

vector comprises a protease cleavage site coding sequence adjacent to the MBP coding

sequence.

27. (withdrawn) An isolated pCWin2-MBP-SBD (pMS₃₉) vector comprising the

sequence set forth in SEQ ID NO:10.

28. (withdrawn) An isolated pCWin2-MBP-SBD (pMS₃₉) vector consisting of the

sequence set forth in SEQ ID NO:10.

29. (withdrawn) An isolated pCWin2-MBP-MCS-SBD (pMXS₃₉) vector comprising the

sequence set forth in SEQ ID NO:11.

30. (withdrawn) An isolated pCWin2-MBP-MCS-SBD (pMXS₃₉) vector consisting of

the sequence set forth in SEQ ID NO:11.

31. (withdrawn) The pCWin2-MBP-SBD (pMS₃₉) expression vector of claim 27,

wherein the pCWin2-MBP-SBD (pMS₃₉) vector comprises a protease cleavage site

coding sequence immediately prior to the start of the C-terminus of the MBP coding

6

sequence.

{W:\DOCS\NJPC\1096\0011us1\00015820.DOC}

US Ser No: 10/585,440 Appl. Filed: 05/08/2007

32. (withdrawn) A method of expressing a protein, said method comprising cloning a nucleic acid encoding said protein into a pCWin1 expression vector as set forth in SEQ

ID NO:1 and expressing said protein therefrom.

33. (original) A method of expressing a protein, said method comprising cloning a

nucleic acid encoding said protein into a pCWin2 expression vector as set forth in SEQ

ID NO:2 and expressing said protein therefrom.

34. (original) A method of expressing a protein, said method comprising cloning a

nucleic acid encoding said protein into a nucleic acid vector selected from the group

consisting of:

a) a pCWin2/MBP expression vector as set forth in SEQ ID NO:3;

b) a pCWin2-MBP-SBD (pMS₃₉) expression vector as set forth in SEQ ID NO:10; and

c) a pCWin2-MBP-MCS-SBD (pMXS₃₉) expression vector as set forth in SEQ ID

NO:11;

and expressing said protein therefrom.

35. (original) The method of any one of claims 32-34, wherein said protein is expressed

in a prokaryotic cell.

{W:\DOCS\NJPC\1096\0011us1\00015820.DOC} US Ser No: 10/585,440

Appl. Filed: 05/08/2007 Response Filed: August 2, 2010